Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Tragara Pharmaceuticals, Inc. may have found a beneficial use for a COX-2 inhibitor in oncology, and it involves using a urine test, not a biopsy, to match non-small cell lung cancer patients with the therapy.

You may also be interested in...

NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges

Biomarker-guided targeted therapy has become a standard approach to oncology R&D, but few new targeted drugs have reached the market for lung cancer. A new wave of research could change that, and improve the outlook for lung cancer treatment.

Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results

The European Medicines Agency issues a formal review, even though the claim had been withdrawn, in order to discourage off-label use.

Will COX-2 + Biomarker = Success? Novartis Tests the Frontiers of Companion Diagnostics

A new genetic blood test that identifies patients at risk of liver toxicities may give Joicela (formerly Prexige) new life.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts